Drug Analysis: Diabetic Nephropathy Market and Forecast Analyst to 2025

Table of Contents

1 Forecast: Diabetic Nephropathy (Published On 17 February 2017)

• Executive Summary


• Market Overview and Trends


• Market Definition and Methodology


• Atrasentan


• Farxiga (Dapagliflozin) Franchise


• Finerenone


• Invokana (Canagliflozin) Franchise


• Jardiance (Empagliflozin) Franchise


• Primary Research Methodology

2 Treatment: Diabetic Nephropathy (Published On 05 February 2018)

• Executive Summary


• Primary Research Methodology


• Disease Definition and Diagnosis


• Patient Segmentation


• Guideline Recommendations


• Prescribing Trends

3 Epidemiology: Diabetic Nephropathy (Published On 05 February 2018)

• Executive Summary


• Disease Background


• Methodology


• Forecast


• Bibliography


• Appendix: Additional Sources

4 Marketed Drugs: Diabetic Nephropathy (Published On 02 February 2018)

• Executive Summary


• Ace Inhibitors


• Angiotensin II Receptor Blockers

5 Pipeline: Diabetic Nephropathy (Published On 02 February 2018)

• Executive Summary


• Clinical Pipeline Overview


• Target Product Profile


• Clinical Trial Design


• Product Profile (Late Stage): Farxiga


• Product Profile (Late Stage): Invokana


• Product Profile (Late Stage): Jardiance


• Product Profile (Late Stage): Atrasentan


• Product Profile (Late Stage): Finerenone

List of Figures
Figure 1: Diabetic nephropathy novel treatment market sales across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Diabetic nephropathy sales of specific drug franchises across the US, Japan, and five major EU markets, 2025
Figure 3: Diabetic nephropathy novel treatment market sales in the US, 2016-25
Figure 4: Diabetic nephropathy novel treatment market sales in the five major EU markets, by country, 2016-25
Figure 5: Methodology flow for diabetic nephropathy
Figure 6: Price sources and calculations, by country
Figure 7: Atrasentan sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Farxiga franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country 2016-25
Figure 10: Invokana franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Jardiance franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 12: Percentage of incident end-stage renal disease patients with diabetes as the primary cause
Figure 13: Patient segmentation by albuminuria and glomerular filtration rate, with US prevalence and risk of kidney outcomes
Figure 14: Type 2 diabetic patients receiving antihypertensives for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 15: Type 2 diabetic patients receiving RAAS inhibitors for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 16: Usage of ACE inhibitors, ARBs, and renin inhibitors for diabetic nephropathy, as a percentage of antihypertensives, among type 2 diabetics, by country
Figure 17: Antihypertensive monotherapy versus combination therapy used to treat diabetic nephropathy in type 1 and type 2 diabetics, by country
Figure 18: Antihypertensive monotherapy vs combination therapy used to treat diabetic nephropathy in type 2 diabetics, b renal impairment stage and country
Figure 19: Percentage of type 2 diabetic patients receiving antidiabetics according to stage of renal impairment, by country
Figure 20: Percentage of type 2 diabetic patients receiving metformin/selected fixed-dose combinations according to stage of renal impairment, by country
Figure 21: Percentage of type 2 diabetic patients receiving DPP-IV inhibitors (including metformin fixed-dose combinations), by stage of renal impairment and country
Figure 22: Ratio of prescribing of Januvia and Tradjenta in each stage of renal impairment compared to prescribing in patients without diabetic nephropathy, by country
Figure 23: Percentage of type 2 diabetic patients receiving SGLT-2 inhibitors (excluding fixed-dose combinations) according to stage of renal impairment, by country
Figure 24: Percentage of type 2 diabetic patients receiving GLP-1 agonists and fixed-ratio combinations with insulin, by stage of renal impairment and country
Figure 25: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, by country
Figure 26: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, PCPs only, by country
Figure 27: Percentage of type 2 diabetic patients receiving sulfonylureas according to stage of renal impairment, by country
Figure 28: Compliance rates of type 2 diabetics with antidiabetic medications according to renal impairment stage, by country
Figure 29: Trends in total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
Figure 30: Farxiga for diabetic nephropathy - SWOT analysis
Figure 31: The author’s drug assessment summary for Farxiga in diabetic nephropathy
Figure 32: The author’s drug assessment summary for Farxiga in diabetic nephropathy
Figure 33: Invokana for diabetic nephropathy - SWOT analysis
Figure 34: The author’s drug assessment summary for Invokana in diabetic nephropathy
Figure 35: The author’s drug assessment summary for Invokana in diabetic nephropathy
Figure 36: Jardiance for diabetic nephropathy - SWOT analysis
Figure 37: The author’s drug assessment summary for Jardiance in diabetic nephropathy
Figure 38: The author’s drug assessment summary for Jardiance in diabetic nephropathy
Figure 39: Atrasentan for diabetic nephropathy - SWOT analysis
Figure 40: The author’s drug assessment summary for atrasentan in diabetic nephropathy
Figure 41: The author’s drug assessment summary for atrasentan in diabetic nephropathy
Figure 42: Finerenone for diabetic nephropathy - SWOT analysis
Figure 43: The author’s drug assessment summary for finerenone in diabetic nephropathy
Figure 44: The author’s drug assessment summary for finerenone in diabetic nephropathy

List of Tables
Table 1: Patient self-reported cardiovascular disease in the diabetic nephropathy and general diabetes populations in the US
Table 2: Summary of drug classes and molecules included in the diabetic nephropathy patient-based forecast
Table 3: Patent expiries occurring in diabetic nephropathy during the forecast period, 2016-25
Table 4: Exchange rates used for calculating prices
Table 5: Atrasentan sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 6: Farxiga franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 7: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 8: Invokana franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 9: Jardiance franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 10: Diabetologists, endocrinologists, and nephrologists surveyed for the diabetic nephropathy primary research study, 2016
Table 11: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
Table 12: Guideline recommendations for blood pressure and glycemic control - kidney organizations
Table 13: Guideline recommendations for blood pressure and glycemic control - diabetes organizations
Table 14: Risk of cardiovascular death and end-stage renal disease according to albuminuria and eGFR (% per year)
Table 15: Proportion of US patients with diabetic nephropathy who are treated with antihypertensives/RAAS inhibitors, by renal stage
Table 16: Sources used for diabetic nephropathy analysis in the US, Japan, and five major EU markets, by country
Table 17: Age-standardized diabetic nephropathy prevalence proportions, by country
Table 18: Segmentation of diabetic nephropathy into chronic kidney disease stage
Table 19: Total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
Table 20: ACE inhibitors class overview
Table 21: ARBs class overview
Table 22: Major ARB trials in type 2 diabetic nephropathy patients with severe albuminuria
Table 23: Phase III pipeline products in development for diabetic nephropathy
Table 24: Cozaar drug profile
Table 25: Cozaar pivotal trial data in diabetic nephropathy
Table 26: Farxiga drug profile
Table 27: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 28: Farxiga Phase III trial in type 2 diabetes with cardiovascular disease or multiple risk factors (includes diabetic nephropathy patients)
Table 29: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 30: Invokana drug profile
Table 31: Invokana Phase III trial in diabetic nephropathy
Table 32: Jardiance drug profile
Table 33: Atrasentan drug profile
Table 34: Atrasentan Phase III trial in diabetic nephropathy
Table 35: Atrasentan Phase IIb pooled results of 12-week studies in diabetic nephropathy
Table 36: Finerenone drug profile
Table 37: Finerenone Phase III trials in diabetic nephropathy
Table 38: Finerenone Phase IIb (ARTS-DN) results in diabetic nephropathy